SCHEMBL10012889

SCHEMBL10012889

COc1ccc(-c2cn3c(=O)c(Cc4ccccc4)nc-3c(Cc3ccccc3)[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.43
▸ HPGD P15428 6/20 0.43
▸ HSD17B10 Q99714 4/20 0.43
▸ ADORA3 P0DMS8 2/20 0.43
▸ TP53 P04637 2/20 0.43
▸ APAF1 O14727 1/20 0.43
▸ ALDH1A1 P00352 8/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HTT P42858 4/20 0.42
▸ LMNA P02545 1/20 0.42
▸ KMT2A Q03164 5/20 0.42
▸ GAA P10253 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PSD A5PKW4 2/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ MAPT P10636 1/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12735455 0.99 ALDH1A1 (0.43) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL4547065 0.97 ALDH1A1 (0.45) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL13484442 0.95 ALDH1A1 (0.42) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL29886558 0.95 ADORA3 (0.40) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL10196895 0.94 MTOR (0.40) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL12735454 0.94 MTOR (0.40) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL19810194 0.92 ALDH1A1 (0.39) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL19206678 0.90 LTB4R (0.47) KDM4EHSD17B10ALDH1A1SMN1; SMN2HTT
SCHEMBL7907590 0.89 KDM4E (0.48) KDM4EHPGDHSD17B10ADORA3TP53
SCHEMBL492636 0.89 LTB4R (0.41) KDM4EHPGDHSD17B10ADORA3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160362388-A1 CHEMILUMINESCENT METHODS AND REAGENTS FOR ANALYTE DETECTION WANG TIANXIN (US) 2016-12-15 — — US disclosed
US-9487520-B2 Coelenterazine derivatives and methods of using same PROMEGA CORPORATION (US) 2016-11-08 — — US disclosed
US-9399657-B2 Chemiluminescent methods and reagents for analyte detection WANG TIANXIN (US) 2016-07-26 — — US disclosed
EP-2454261-B1 IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE UNIV SIENA (IT) 2014-11-19 — — EP disclosed
US-8546147-B2 Imidazo[1,2-α]pyrazin-3(7H)-one derivatives bearing a new electron-rich structure UNIVERSITA DEGLI STUDI DI SIENA (IT) 2013-10-01 — — US disclosed
US-20120171703-A1 IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE UNIVERSITÁ DEGLI STUDI DI SIENA (IT) 2012-07-05 — — US disclosed
US-20110097753-A1 Chemiluminescent methods and reagents for analyte detection WANG TIANXIN 2011-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160362388-A1 CHEMILUMINESCENT METHODS AND REAGENTS FOR ANALYTE DETECTION UCHL1, LCT, SPR KDM4E 2396/4885HPGD 827/4885HSD17B10 467/4885
US-20120171703-A1 IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE GLB1, NDUFV1, IK KDM4E 4676/4885HPGD 377/4885HSD17B10 1662/4885
US-20110097753-A1 Chemiluminescent methods and reagents for analyte detection UCHL1, LCT, SPR KDM4E 2396/4885HPGD 827/4885HSD17B10 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback